×
About 20,363 results

ALLMedicine Pulmonary Fibrosis Center

Research & Reviews  9,663 results

Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibros...
https://doi.org/10.1111/crj.13223
The Clinical Respiratory Journal; Luo Z, Yang L et. al.

May 27th, 2020 - Relatively little is known about the effects of mechanical ventilation (MV; including invasive MV [IMV] and noninvasive ventilation) on clinical outcomes of patients with idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated...

Amelioration of paraquat-induced pulmonary fibrosis in mice by regulating miR-140-5p ex...
https://doi.org/10.1177/2058738420923911
International Journal of Immunopathology and Pharmacology; Dong MN, Xiao Y et. al.

May 27th, 2020 - Intravenous Xuebijing (XBJ) therapy suppresses paraquat (PQ)-induced pulmonary fibrosis. However, the mechanism underlying this suppression remains unknown. This work aimed to analyze the miR-140-5p-induced effects of XBJ injection on PQ-induced p...

lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via f...
https://doi.org/10.18632/aging.103176
Aging Yang Y, Tai W et. al.

May 26th, 2020 - Pulmonary fibrosis (PF) is a lethal fibrotic lung disease. The role of lncRNAs in multiple diseases has been confirmed, but the role and mechanism of lncRNA zinc finger antisense 1 (ZFAS1) in the progression of PF need to be elucidated further. He...

Amniotic MSCs reduce pulmonary fibrosis by hampering lung B-cell recruitment, retention...
https://doi.org/10.1002/sctm.20-0068
Stem Cells Translational Medicine REFERENCES; Cargnoni A, Romele P et. al.

May 25th, 2020 - Growing evidence suggests a mechanistic link between inflammation and the development and progression of fibrotic processes. Mesenchymal stromal cells derived from the human amniotic membrane (hAMSCs), which display marked immunomodulatory propert...

Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopa...
https://doi.org/10.1016/j.chest.2020.04.066
Chest Adegunsoye A, Alqalyoobi S et. al.

May 25th, 2020 - A number of circulating plasma biomarkers have been shown to predict survival in patients with idiopathic pulmonary fibrosis (IPF), but most were identified prior to the use of anti-fibrotic therapy (AF) in this population. Because pirfenidone and...

see more →

Guidelines  25 results

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice G...
https://www.atsjournals.org/doi/10.1164/rccm.201807-1255ST
Raghu, G.

Aug 31st, 2018 - This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and.

Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society ...
https://cts-sct.ca/wp-content/uploads/2018/02/Evaluation-of-pts-w_ILD-paper.pdf
Kerri A. Johannson

Aug 21st, 2017 - Fibrotic ILD represents a large heterogeneous group of disorders that are challenging to diagnose. The evaluation of patients with fibrotic ILD should include a thorough history, physical examination, basic serological testing, pulmonary function.

Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fib...
http://www.thoracic.org/statements/resources/interstitial-lung-disease/animal-models-pulm-fibrosis.pdf
R. Gisli Jenkins

Apr 30th, 2017 - Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clini.

Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment.
https://doi.org/10.1159/000464332
Respiration; International Review of Thoracic Diseases; Funke-Chambour M, Azzola A et. al.

Mar 27th, 2017 - Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the c...

The Intersection of GERD, Aspiration, and Lung Transplantation.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948126
Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A; Patti MG, Vela MF et. al.

May 24th, 2016 - Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophagea...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  10,113 results

Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibros...
https://doi.org/10.1111/crj.13223
The Clinical Respiratory Journal; Luo Z, Yang L et. al.

May 27th, 2020 - Relatively little is known about the effects of mechanical ventilation (MV; including invasive MV [IMV] and noninvasive ventilation) on clinical outcomes of patients with idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated...

Amelioration of paraquat-induced pulmonary fibrosis in mice by regulating miR-140-5p ex...
https://doi.org/10.1177/2058738420923911
International Journal of Immunopathology and Pharmacology; Dong MN, Xiao Y et. al.

May 27th, 2020 - Intravenous Xuebijing (XBJ) therapy suppresses paraquat (PQ)-induced pulmonary fibrosis. However, the mechanism underlying this suppression remains unknown. This work aimed to analyze the miR-140-5p-induced effects of XBJ injection on PQ-induced p...

lncRNA ZFAS1 promotes lung fibroblast-to-myofibroblast transition and ferroptosis via f...
https://doi.org/10.18632/aging.103176
Aging Yang Y, Tai W et. al.

May 26th, 2020 - Pulmonary fibrosis (PF) is a lethal fibrotic lung disease. The role of lncRNAs in multiple diseases has been confirmed, but the role and mechanism of lncRNA zinc finger antisense 1 (ZFAS1) in the progression of PF need to be elucidated further. He...

Amniotic MSCs reduce pulmonary fibrosis by hampering lung B-cell recruitment, retention...
https://doi.org/10.1002/sctm.20-0068
Stem Cells Translational Medicine REFERENCES; Cargnoni A, Romele P et. al.

May 25th, 2020 - Growing evidence suggests a mechanistic link between inflammation and the development and progression of fibrotic processes. Mesenchymal stromal cells derived from the human amniotic membrane (hAMSCs), which display marked immunomodulatory propert...

Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopa...
https://doi.org/10.1016/j.chest.2020.04.066
Chest Adegunsoye A, Alqalyoobi S et. al.

May 25th, 2020 - A number of circulating plasma biomarkers have been shown to predict survival in patients with idiopathic pulmonary fibrosis (IPF), but most were identified prior to the use of anti-fibrotic therapy (AF) in this population. Because pirfenidone and...

see more →

News  535 results

Fast Five Quiz: Idiopathic Pulmonary Fibrosis
https://www.medscape.com/viewarticle/925452

Apr 29th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease characterized by progressive lung scarring. IPF is described on imaging as well as histopathologically by the usual interstitial pneumonia (UIP) pattern. Patients have incre...

Fast Five Quiz: Idiopathic Pulmonary Fibrosis Imaging
https://www.medscape.com/viewarticle/925458

Apr 29th, 2020 - Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown etiology that affects approximately 3 million individuals worldwide. IPF is characterized by gradual worsening of dyspnea an...

FDA broadens nintedanib interstitial lung disease indication
https://www.mdedge.com/internalmedicine/article/218826/pulmonology/fda-broadens-nintedanib-interstitial-lung-disease?channel=39313
Mitchel L. Zoler

Mar 11th, 2020 - A new indication for the tyrosine kinase inhibitor nintedanib approved by the Food and Drug Administration on March 9, 2020, broadened the drug’s targeted population to include patients with chronic fibrosing interstitial lung diseases with a prog.

Roche Pushes to Kick-Start Lung Therapy Esbriet After Big Writedown
https://www.medscape.com/viewarticle/926124

Mar 4th, 2020 - ZURICH, March 3 (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable interstitial lung disease (uILD), the company said on Tuesday, as it aims to lift disappointing revenue by expanding conditions for which it ...

Roche pushes to kick-start lung therapy Esbriet after big writedown
https://www.reuters.com/article/us-roche-esbriet/roche-pushes-to-kick-start-lung-therapy-esbriet-after-big-writedown-idUSKBN20Q21O

Mar 3rd, 2020 - FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) - Roche has won U.S. breakthrough therapy status for Esbriet for unclassifiable int...

see more →

Patient Education  23 results see all →